Brean Capital assumes coverage of Nektar Therapeutics (NASDAQ: NKTR ) with Buy rating and $23 price target on strong growth in royalties from recent and future new launches. "In our view, Nektar's ...
- Business Wire•2 days ago
AstraZeneca today announced that the US Food and Drug Administration has approved a blood-based companion diagnostic for TAGRISSO® . The companion diagnostic for TAGRISSO is the only FDA-approved and clinically validated companion diagnostic test that uses either tissue or a blood sample to confirm the presence of a T790M mutation in patients with metastatic epidermal growth factor receptor mutation-positive ...
AstraZeneca PLC (AZN)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||32.62 x 100|
|Ask||33.00 x 500|
|Day's Range||32.86 - 33.17|
|52wk Range||26.97 - 35.04|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||37.55|
|Avg Vol (3m)||5,981,759|
|Dividend & Yield||0.90 (2.72%)|